Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trampoline study of salt intake and amiloride in ADPKD
NL-OMON60746Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of amiloride and sodium chloride in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Erasmus MC. Primary endpoints: Pulse wave velocity difference between high salt and placebo groups, Pulse wave velocity before versus after amiloride in the high salt group and 1 more. Started May 2022; status: completed.
02
Drugs
amiloridesodium chloride
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON60746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60746.